Tumor regression by combined immunotherapy and hyperthermia using magnetic nanoparticles in an experimental subcutaneous murine melanoma

Immunotherapy (IT) has become an accepted therapeutic modality. We previously reported that intracellular hyperthermia (IH) using magnetic nanoparticles induces antitumor immunity. We undertook these studies in order to study the combined effects of IT and IH on melanoma. Magnetite cationic liposomes (MCLs) have a positive surface charge and generate heat in an alternating magnetic field (AMF) due to hysteresis loss. MCLs were injected into a B16 melanoma nodule in C57BL/6 mice, which were subjected to AMF for 30 min. The temperature at the tumor reached 43°C and was maintained by controlling the magnetic field intensity. At 24 h after IH, interleukin‐2 (IL‐2) or granulocyte macrophage‐colony stimulating factor (GM‐CSF) was injected directly into the melanoma. Mice were divided into six groups: group I (control), group II (IH), group III (IL‐2), group IV (GM‐CSF), group V (IH+IL‐2), and group VI (IH+GM‐CSF). Complete regression of tumors was observed in mice of groups V and VI (75% (6/ 8) and 40% (4/10) of the mice, respectively), while no tumor regression was observed in mice of the other groups. This study supports the combined use of IT and IH using MCLs in patients with advanced malignancies. (Cancer Sci 2003; 94: 308–313)

[1]  H. Honda,et al.  Anticancer effect and immune induction by hyperthermia of malignant melanoma using magnetite cationic liposomes , 2003, Melanoma research.

[2]  H. Honda,et al.  Heat shock protein 70 expression induces antitumor immunity during intracellular hyperthermia using magnetite nanoparticles , 2003, Cancer Immunology, Immunotherapy.

[3]  H. Honda,et al.  Augmentation of MHC class I antigen presentation via heat shock protein expression by hyperthermia , 2001, Cancer Immunology, Immunotherapy.

[4]  S. Kasaoka,et al.  Tumor regression by inductive hyperthermia combined with hepatic embolization using dextran magnetite-incorporated microspheres in rats. , 2000, International journal of oncology.

[5]  A. Melcher,et al.  Heat shock protein 70 induced during tumor cell killing induces Th1 cytokines and targets immature dendritic cell precursors to enhance antigen uptake. , 1999, Journal of immunology.

[6]  Jun Yoshida,et al.  Intracellular hyperthermia for cancer using magnetite cationic liposomes: an in vivo study. , 1999, Japanese journal of cancer research : Gann.

[7]  J. Mulé,et al.  Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[8]  A. Menoret,et al.  Heat-shock protein-based anticancer immunotherapy: an idea whose time has come. , 1998, Seminars in oncology.

[9]  H. Honda,et al.  Antitumor Immunity Induction by Intracellular Hyperthermia Using Magnetite Cationic Liposomes , 1998, Japanese journal of cancer research : Gann.

[10]  P. Srivastava,et al.  Heat shock proteins come of age: primitive functions acquire new roles in an adaptive world. , 1998, Immunity.

[11]  H. Band,et al.  Hsp72-mediated augmentation of MHC class I surface expression and endogenous antigen presentation. , 1998, International immunology.

[12]  D. Hanahan,et al.  Self Antigens Expressed by Solid Tumors Do Not Efficiently Stimulate Naive or Activated T Cells: Implications for Immunotherapy , 1997, The Journal of experimental medicine.

[13]  Jun Yoshida,et al.  Intracellular Hyperthermia for Cancer Using Magnetite Cationic Liposomes: Ex vivo Study , 1996, Japanese journal of cancer research : Gann.

[14]  P. Matzinger,et al.  Is cancer dangerous to the immune system? , 1996, Seminars in immunology.

[15]  P. Srivastava,et al.  A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. , 1995, Science.

[16]  Takeshi Kobayashi,et al.  Heat Properties of Magnetoliposomes for Local Hyperthermia , 1994 .

[17]  E. Jaffee,et al.  Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[18]  M. Socinski,et al.  Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. , 1988, The New England journal of medicine.

[19]  R. Bast,et al.  Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. , 1988, The New England journal of medicine.

[20]  J. Gutterman,et al.  Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. , 1987, The New England journal of medicine.

[21]  J. Groopman,et al.  Effect of recombinant human granulocyte-macrophage colony-stimulating factor on myelopoiesis in the acquired immunodeficiency syndrome. , 1987, The New England journal of medicine.

[22]  J. Horiguchi,et al.  Expression of the macrophage-specific colony-stimulating factor in human monocytes treated with granulocyte-macrophage colony-stimulating factor. , 1987, Blood.

[23]  Y Onoyama,et al.  Multi‐institutional studies on hyperthermia using an 8‐MHz radiofrequency capacitive heating device (thermotron RF‐8) in combination with radiation for cancer therapy , 1986, Cancer.

[24]  D. Golde,et al.  Purified human granulocyte-macrophage colony-stimulating factor: direct action on neutrophils. , 1984, Science.

[25]  J. Subjeck,et al.  Heat shock proteins and protection of proliferation and translation in mammalian cells. , 1984, Cancer research.

[26]  C. Owen,et al.  Magnetic labeling and cell sorting. , 1984, Journal of immunological methods.

[27]  M. Doyle,et al.  Biological activity of recombinant human interleukin-2 produced in Escherichia coli. , 1984, Science.

[28]  T. Flotte,et al.  Dendritic cell and macrophage staining by monoclonal antibodies in tissue sections and epidermal sheets. , 1983, The American journal of pathology.

[29]  M. McMahon,et al.  Hyperthermia and the heat-shock proteins of HeLa cells. , 1982, British Journal of Cancer.

[30]  W. Farrar,et al.  Regulation of the production of immune interferon and cytotoxic T lymphocytes by interleukin 2. , 1981, Journal of immunology.

[31]  A. Burgess,et al.  The nature and action of granulocyte-macrophage colony stimulating factors. , 1980, Blood.

[32]  J. Zee.  Heating the patient : a promising approach ? , 2002 .

[33]  R. Kiessling,et al.  Human heat shock protein 70 peptide complexes specifically activate antimelanoma T cells. , 2001, Cancer research.

[34]  Edgar G. Engleman,et al.  Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells , 1996, Nature Medicine.

[35]  H. Honda,et al.  Intracellular hyperthermia for cancer using magnetite cationic liposomes: in vitro study. , 1996, Japanese journal of cancer research : Gann.

[36]  P. Matzinger.  Tolerance, danger, and the extended family. , 1994, Annual review of immunology.

[37]  P. Wust,et al.  Inductive heating of ferrimagnetic particles and magnetic fluids: physical evaluation of their potential for hyperthermia. , 1993, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[38]  R. Steinman,et al.  The dendritic cell system and its role in immunogenicity. , 1991, Annual review of immunology.

[39]  J. Hadden.  Recent advances in the preclinical and clinical immunopharmacology of interleukin-2: emphasis on IL-2 as an immunorestorative agent. , 1988, Cancer detection and prevention.

[40]  Hadden Jw.  Recent advances in the preclinical and clinical immunopharmacology of interleukin-2: emphasis on IL-2 as an immunorestorative agent. , 1988 .